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Abstract
Data from both toxin-based and gene-based models suggest that dysfunction of the microtubule system contributes to the
pathogenesis of Parkinson’s disease, even if, at present, no evidence of alterations of microtubules in vivo or in patients is
available. Here we analyze cytoskeleton organization in primary fibroblasts deriving from patients with idiopathic or genetic
Parkinson’s disease, focusing on mutations in parkin and leucine-rich repeat kinase 2. Our analyses reveal that genetic and
likely idiopathic pathology affects cytoskeletal organization and stability, without any activation of autophagy or apoptosis.
All parkinsonian fibroblasts have a reduced microtubule mass, represented by a higher fraction of unpolymerized tubulin in
respect to control cells, and display significant changes in microtubule stability-related signaling pathways. Furthermore, we
show that the reduction of microtubule mass is so closely related to the alteration of cell morphology and behavior that
both pharmacological treatment with microtubule-targeted drugs, and genetic approaches, by transfecting the wild type
parkin or leucine-rich repeat kinase 2, restore the proper microtubule stability and are able to rescue cell architecture. Taken
together, our results suggest that microtubule destabilization is a point of convergence of genetic and idiopathic forms of
parkinsonism and highlight, for the first time, that microtubule dysfunction occurs in patients and not only in experimental
models of Parkinson’s disease. Therefore, these data contribute to the knowledge on molecular and cellular events
underlying Parkinson’s disease and, revealing that correction of microtubule defects restores control phenotype, may offer a
new therapeutic target for the management of the disease.
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Introduction
Parkinson’s disease (PD) is the most common motor neurode-
generative disorder, characterized by the loss of dopaminergic
neurons in the substantia nigra. Although it has been extensively
studied, its molecular etiopathogenesis is not well understood [1].
Monogenic forms of the disorder account for up to 10% of
parkinsonisms, and mutated parkin and leucine-rich repeat kinase 2
(LRRK2) are responsible for the majority of genetic PD cases [2].
Although parkin and LRRK2 seem to act on different physiolog-
ical processes, being parkin an E3 ligase catalyzing the addition of
ubiquitin to target proteins [3] and LRRK2 a multi-domain
protein involved in the regulation of neuronal process elongation
[4], their actions converge on microtubules (MTs) [5,6].
MTs are cytoskeletal polymers built up by a/b tubulin
heterodimers, which participate in many cellular functions, such
as morphology acquisition, cell migration and intracellular
transport. MTs usually show a dynamic behavior switching
between slow growth and rapid depolymerization [7]. a-Tubulin
post-translational modifications (PTMs) correlate with subsets of
MTs that behave differently: tyrosinated (Tyr) MTs are the most
dynamic subset, acetylated (Ac) or detyrosinated (deTyr) MTs are
more stable pools [8].
Several recent studies have highlighted the crucial role of MTs
during PD progression. Indeed, many PD-linked proteins, such as
parkin, LRRK2 and a-synuclein, are able to modulate the stability
of MTs [9–11]. However, nothing has been reported about
their ability to regulate a-tubulin PTMs. Further evidence has
been obtained from neurotoxic models of PD: both rotenone and
1-methyl-4-phenyl-piridinium (MPP+) destabilize MTs in vitro
[12,13] and in neuronal cells [14,15]. Moreover, we have
demonstrated the importance of a-tubulin PTMs in PD pathology,
reporting that MPP+ causes an early change in MT stability [15].
All these data highlight the importance of MT dysfunction in PD
experimental models, but the demonstration of MT involvement
in human disease is still lacking.
Post-mortem analyses of human brain could reveal molecular
alterations present in the very late phases of neurodegenerative
diseases, with the great disadvantage of working with dead tissues.
On the other hand, peripheral tissues are a unique source of
human living cells, and in the last few years they have become
reliable models for the identification of molecular alterations and
possible therapeutic targets in neurodegenerative disorders,
including PD [16–19]. As recently highlighted [20], human skin
fibroblasts are an easy available and robust PD experimental
model, due to some of their peculiarities: they express most of the
gene relevant to PD and mirror the polygenic risk factors of
specific patient; they comprise the chronological and biological
aging other than the environmental exposition, reflecting all the
cumulative cell damage of the patient; they make very dynamic
contacts as neurons do.
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On this basis, here we analyzed fibroblasts from patients with
idiopathic PD or from patients carrying mutations in either parkin
or LRRK2 to establish whether MT alterations are present in
baseline conditions or not. The principal findings we report are the
considerable reduction in fibroblast MT mass in PD patients with
respect to controls and the rescue resulting from either pharma-
cological or genetic approaches that stabilize MT system. Thus,
our results highlight that MT destabilization occurs in PD patients
and it seems to represent a point of convergence of genetic and
idiopathic parkinsonisms.
Materials and Methods
Ethics Statement and Patients
Primary fibroblasts were obtained by skin biopsies from 25
individuals, whose phenotype and genotype data are summarized
in Table 1, and that included 10 healthy volunteers as control
group and 15 patients affected by PD, divided into three different
pathological groups. Age distribution of each group is reported in
the scatter plot (Figure S1), and the statistical analyses did not
reveal significant differences in age between control and patient
groups. All patients were examined by movement disorder
neurologists and clinical diagnosis of PD was established
according to the UK Parkinson Disease Society Brain Bank
criteria [21,22]. The LRRK2 G2019S missense mutation and
mutations on the parkin (PRKN) gene were screened as previously
described [23,24].
The study was approved by the local ethics committee (Istituti
Clinici di Perfezionamento, July 13th 2010) and all participants
gave written informed consent.
Cell Culture and Morphometric Analyses
Human fibroblasts were cultured in RPMI 1640 (Hyclone,
Logan, UT, USA) containing 15% foetal bovine serum (HyClone)
supplemented with 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, at 37uC in a humidified atmosphere,
5% CO2. For transfection experiments, human fibroblasts were
plated at the density of 5000 cells/well. The day after cells were
transiently transfected using Lipofectamine 2000 (Invitrogen) (1:3
DNA to Lipofectamine ratio, 1.5 mg of DNA per well) and
analyzed 24 h after transfection. All the plasmids for parkin
silencing and over-expression (Figure S2) were supplied by
Dr. Sassone (IRCCS Istituto Auxologico Italiano, Milano, Italy)
The plasmids encoding untagged human parkin was generated by
in-frame insertion of a PCR-amplified DNA fragment encoding
human parkin into the pcDNA4-Myc-HIS vector. The fragment
was then subcloned in the pECFP-C1 vector to produce in frame
CFP-tagged parkin. As negative control a plasmid encoding EGFP
mRNA was used. Plasmid encoding short hairpin RNA (shRNA)
selective for human parkin was generated with the GatewayH
Table 1. Phenotype and genotype characterisation of investigated individuals.
COD PHENOTYPE GENOTYPE SEX AGEa AGE OF ONSET b
CONT FFF0311991 HEALTHY F 39
FFF0541986 HEALTHY M 41
FFF0191992 HEALTHY M 43
FFF0531978 HEALTHY F 44
FFF0961978 HEALTHY M 44
FFF0401991 HEALTHY F 46
FFF0521978 HEALTHY M 51
FFF0421991 HEALTHY M 54
FFF0422011 HEALTHY M 69
FFF0412011 HEALTHY F 64
PARK FFF0302009 AFFECTED c.C815G (p.C238W); exon 6–7 del. F 57 30
FFF1072009 AFFECTED c.del202_203AG (p.Q34/X43); exon 4–6 del. M 53 40
FFF0142009 AFFECTED c.C924T (p.R275W); exon 3 del. F 41 22
FFF0292009 AFFECTED exon 3 del (homozygotes) F 69 39
FFF0902009 AFFECTED c.del202_203AG (p.Q34/X43) (homozygotes) M 51 20
FFF0072010 AFFECTED c.del202_203AG (p.Q34/X43) (homozygotes) F 59 39
LRRK2 FFF0642009 AFFECTED p.G2019S (heterozygotes) F 58 41
FFF0962009 AFFECTED p.G2019S (heterozygotes) M 47 40
FFF0112010 AFFECTED p.G2019S (homozygotes) M 68 63
FFF0092009 AFFECTED p.G2019S (heterozygotes) M 46 35
FFF0502009 AFFECTED p.G2019S (heterozygotes) F 61 46
FFF0452009 AFFECTED p.G2019S (heterozygotes) M 79 72
PD FFF0562009 AFFECTED X M 71 66
FFF0542009 AFFECTED X M 68 52
FFF0202010 AFFECTED X M 50 42
aAge at time of skin biopsy and establishment of fibroblast cell line.
bThe age at which the patient first noticed a PD-related symptom was considered the age of onset of the disease.
doi:10.1371/journal.pone.0037467.t001
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recombination cloning technology (Invitrogen, Carlsbad, CA).
The sequence is: sh-183: 59 CACCGGATCAGCAGAG-
CATTGTTCACGAATGAACAATGCTCTGCTGATCC 39.
The double stranded DNA oligo encoding a sense-loop-
antisense sequence to the targeted gene was cloned into the
pENTRTM/U6 entry vector. The shRNA cassettes was then
transferred into the plasmid pBLOCK-iT 3-DEST, suitable for
GeneticinH selection. As negative control a plasmid encoding
shRNA for bacterial lacZ mRNA was used. LRRK2 constructs
[25] were kindly gifted by Dr. Greggio (Department of Biology,
University of Padova, Padova, Italy).
For pharmacological treatment, control and patient fibroblasts
were plated at the density of 5000 cells/well. The day after cells
were incubated 2 h with 10 mM of Paclitaxel dissolved in
methanol (Sigma-Aldrich, St Louis, MO), Nocodazole dissolved
in methanol (Sigma-Aldrich) or Thiocolchine dissolved in DMSO
(provided by Dr. Passarella, Dep. of Industrial and Organic
Chemistry, Univ. of Milan, Italy) and then analyzed.
In all assays, the fibroblast passage numbers were matched
(,10). For morphometric analyses, 5 to 10 random images per
plate were captured using an Axiovert 200 M microscope (Zeiss,
Oberkochen, Germany), and analyses were made using digital
image processing software (Interactive measurement module,
Axiovision, Zeiss). All cells in each image were analyzed.
Immunofluorescence Microscopy
Cells were fixed with cold methanol or 4% paraformaldehyde
and incubated with the following primary antibodies and probes:
a-tubulin mouse IgG (clone B-5-1-2, Sigma-Aldrich, St Louis,
MO); deTyr tubulin rabbit IgG (Chemicon, Temecula, CA); Tyr
tubulin mouse IgG (clone TUB-1A2, Sigma-Aldrich); Ac tubulin
mouse IgG (clone 6-11B-1, Sigma-Aldrich); vimentin mouse IgG
(clone V6, Sigma-Aldrich); Phalloidin-Tetramethylrhodamine B
isothiocyanate and 49,6-Diamidino-2-phenylindole dihydrochlo-
ride (Sigma-Aldrich). As secondary antibodies we used Alexa
FluorTM 568 donkey anti-mouse, and Alexa FluorTM 488 goat
anti-rabbit (Invitrogen, Carlsbad, CA). The coverslips were
mounted in MowiolH (Calbiochem, San Diego, CA)–DABCO
(Sigma-Aldrich, St Louis, MO) and examined with the Axiovert
200 M microscope.
Western Blot Analysis
Whole cell extracts, Triton X-100 soluble and insoluble
fractions of human fibroblasts were prepared as previously
reported [26]. Equal proportions of each fraction or protein
samples from whole cell extracts (25 mg per lane) were separated
by 7 or 15% SDS-PAGE and blotted onto PDVF membranes
(ImmobilonTM-P, Millipore, Billerica, MA). Membranes were
probed with the following antibodies: a-tubulin mouse IgG (clone
B-5-1-2, Sigma-Aldrich, St Louis, MO); b-tubulin mouse IgG
(clone Tub 2.1, Sigma-Aldrich); deTyr tubulin rabbit IgG
(Chemicon, Temecula, CA); Tyr tubulin mouse IgG (clone
TUB-1A2, Sigma-Aldrich); Ac tubulin mouse IgG (clone 6-11B-
1, Sigma-Aldrich); microtubule-associated protein 1 light chain 3
rabbit IgG (Sigma-Aldrich); vimentin mouse IgG (clone V6,
Sigma-Aldrich); actin mouse IgM (N350, Amersham, Little
Chalfont, UK); Caspase 3 rabbit IgG (Enzo Life Sciences Ag.,
Lausen, Switzerland), GADPH mouse IgG (Biogenesis, Poole,
UK); Heat Shock Protein 70 mouse IgG (clone 3A3, Chemicon);
Glycogen synthase kinase 3 beta rabbit IgG (Abcam, Cambride,
UK); Phospho-Glycogen synthase kinase 3 beta (Ser9) rabbit IgG
(Cell Signaling Technology, Beverly, MA); p38 alpha MAP Kinase
mouse IgG (clone L53F8, Cell Signaling Technology); Phospho-
p38 MAP Kinase (Thr180/Tyr182) rabbit IgG (clone 3D7, Cell
Signaling Technology); p44/42 MAPK (Erk1/2) rabbit IgG (clone
137F5, Cell Signaling Technology); Phospho-p44/42 MAPK
(Thr202/Tyr204) rabbit IgG (clone D13.14.4E, Cell Signaling
Technology); parkin mouse IgG (clone prk8, Sigma-Aldrich).
Next, immunoblots were incubated with HRP donkey anti-mouse
IgG and HRP goat anti-rabbit IgG (Pierce, Rockfort, IL) or HRP
goat anti-mouse IgM (Sigma-Aldrich), and developed using
enhanced chemioluminescence (Supersignal West Pico Chemilu-
minescent, Pierce, Rockford, IL). Immunoblots were scanned with
JX-330 color image scanner (Sharp Electronics Europe) and
analyzed by ImageJ software (National Institute of Health).
Statistical Analysis
Statistical analysis was performed using STATISTICA (StatSoft
Inc., Tulsa, OK), and significant differences of PD patients versus
control fibroblasts, or between groups in rescue experiments, were
assessed by one-way ANOVA with Tukey HSD post hoc test. Data
are expressed as means 6 SEM.
Results
Morphological Alterations Characterize PD Fibroblasts
We observed striking differences between the cultured human
fibroblasts collected from PD patients and those collected from
controls in terms of morphology and behavior. Looking at the
general morphology of the cells, control fibroblasts were elongated
and flanked each other, whereas fibroblasts from PD patients were
wider, larger, and partly overlapped, as they lost the ability to
sense each other (Figures 1 and 2). Morphometric analyses
underlined the decrease of the ratio between maximum and
minimum axis (Figure 1B), and the measurement of the area
corroborated the idea that PD fibroblasts were larger than control
cells (Figure 1C), at least in the presence of mutated parkin or
LRRK2. Furthermore, parkinsonian fibroblasts showed a different
spatial organization, being much more enshrouded, as pointed out
by the increase in overlapping regions (Figure 1D). These data
highlight that fibroblasts deriving from PD patients are charac-
terized by altered morphology.
PD Fibroblasts Show Subtle Cytoskeleton Differences
Since changes in cell morphology are likely mediated by
rearrangements of cytoskeletal architecture, we investigated the
levels (Figure 2A–B) and organization (Figure 2C) of all the
three cytoskeletal polymers: intermediate filaments (IFs), MTs
and actin filaments. The levels and localization of vimentin, the
principal constituent of the fibroblast IFs, did not vary in PD
fibroblasts. Tubulin levels showed changes only in patients
carrying parkin mutations, whereas MT organization did not
appear to change in any of the experimental groups. It has
been reported that parkin promotes a- and b-tubulin degrada-
tion and that its PD-linked mutations remove this ability [5];
thus, the enrichment of b-tubulin in patients with parkin
mutation is not surprising. On the contrary, a-tubulin levels
were unexpectedly unchanged, suggesting possible different
regulatory mechanisms that need future and deeper investiga-
tions. Finally, we observed a dramatic increase in actin levels in
patients with idiopathic PD; phalloidin staining revealed a
higher amount of stress fibers that appeared to be randomly
oriented whereas in the other experimental groups they were
aligned with the major axis of the cells. Thus, these data
demonstrate that alterations of the cytoskeleton occur in
fibroblasts obtained from patients with parkin mutations and
from idiopathic PD patients.
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Impairment of MT Stability is Shared by PD Fibroblasts
Since we have already reported that MT stability plays a crucial
role in cultured PC12 cells exposed to MPP+ [15], we undertook
an in-depth analysis of a-tubulin PTMs and MT mass in human
fibroblasts. Western blotting (Figure 3A–B) and immunofluores-
cence analyses (Figure S3) revealed severe alterations of tubulin
PTMs in PD fibroblasts. Parkin mutations induced an increase in
Tyr tubulin levels (Figure 3B, dark grey bars), meaning that in the
presence of mutated parkin the MT system seemed to be more
dynamic. On the other hand, LRRK2 mutation (Figure 3B, light
grey bars) caused the enrichment of Ac tubulin, and fibroblasts
from patients with idiopathic PD (Figure 3B, black bars) showed a
significant increase in deTyr tubulin levels, suggesting that MT
(over)stabilization has occurred. The LRRK2-mediated MT
stabilization agrees with the results of Gillardon [10], showing
that G2019S mutation, the same mutation carried by fibroblasts
used here, promotes phosphorylation of b-tubulin and enhances
MT stability. We looked further at the a-tubulin PTMs
localization (Figure S3). Control cells showed an intense perinu-
clear Ac tubulin decoration, whereas Ac MTs filled the entire cell
body of PD fibroblasts, suggesting that this particular subset of
stable MTs had spread, interfering with cell morphology and
behavior. Taken together, all these data point out that the
alteration of MT stability seems to be a common feature of PD
patient fibroblasts. As it has already been reported that PD-
inducing neurotoxins affect the state of tubulin polymerization
in vitro and in neuronal cells [12–15], we wondered whether the
observed changes in MT stability were correlated with abnormal
MT mass in patient fibroblasts. By Western blotting and
densitometric analyses (Figure 3C–D) we evaluated the amount
of a-tubulin associated with Triton-soluble, i.e. dimeric pool
(Dim), and with Triton-insoluble fraction, polymerized MT
fraction (MT). The ratio between free a-tubulin versus a-tubulin
incorporated into MTs was significantly increased in PD
fibroblasts in respect to control cells (Figure 3D), meaning that
polymerized MTs were reduced. Thus, our work shows that MT
depolymerization is shared by all patient fibroblasts here analyzed
and obtained from idiopathic and genetic PD.
GSK3b Phosphorylation is Reduced in PD Fibroblasts
Looking for a possible explanation for the observed MT
destabilization in PD fibroblasts, it is reasonable that Parkin and
LRRK2 mutations directly impact MT stability [9,10]. However,
since MT depolymerization is observed also in idiopathic PD
fibroblasts, we decided to evaluate the potential implication of
signaling pathways converging on MT system. Therefore, in all
the PD fibroblast groups, we investigated the level and the activity
of glycogen synthase kinase 3 beta (GSK3b), p38 protein (p38) and
extracellular signal-related kinases (Erk) that regulate MT stability
through the phosphorylation of MT-associated proteins (MAPs).
As shown in figure 4, the levels of total GSK3b were highly
variable but they did not reach any statistical significance, whereas
GSK3b phosphorylation was significantly reduced in all classes of
PD fibroblasts (Figure 4C). Total p38 showed a significant
reduction only in the presence of mutant LRRK2, whereas
phospho-p38 was completely unchanged. On the other hand,
LRRK2 induced also a slight decrease of Erk and the significant
elevation of phospho-Erk; accordingly to Ren and colleagues [27],
fibroblasts from patients with parkin mutation displayed an
increase of Erk phosphorylation, although without statistical
significance. Nevertheless, phosphorylated GSK3b is the inactive
form and the phosphorylation of MAPs by GSK3b promotes their
detachment from MT walls [28]. Therefore, showing the
significant activation of GSK3b, our data offer a possible
mechanistic explanation for the observed MT destabilization in
idiopathic PD fibroblasts, but also in cells deriving from patients
with genetic cases of the pathology.
Figure 1. Morphological alterations characterize PD fibroblasts. (A) Representative phase contrast micrographs of cultured human
fibroblasts of healthy and PD affected people. Scale bar: 25 mm. Morphometric analysis showed reduced ratio between maximum and minimum axes
in parkinsonian fibroblast (B) and increased area in the presence of mutated parkin or LRRK2 (C). (D) Histogram showing the increased number of
overlapping regions between cells in patient fibroblasts. *p,0.05 and ***p,0.005 vs control according to ANOVA, Tukey HSD post hoc test. All values
are expressed as mean6 SEM. CONT= control (N = 10); PARK=patients with mutations of parkin (N = 6); LRRK2=patients carrying mutations in LRRK2
(N = 6); PD= idiopathic Parkinson’s disease patients (N = 3).
doi:10.1371/journal.pone.0037467.g001
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Stress-induced Pathways are not Activated in
PD Fibroblasts
MT stability is crucial for the activation of apoptosis and
autophagy [29,30], processes variously related to neurodegener-
ation in PD [31]. Thus, we decided to analyze the levels of caspase
3 (CASP 3), which is a terminal executioner of apoptosis, and heat
shock protein 70 (HSP 70), which is a molecular chaperone with
anti-apoptotic properties that prevents aggregation and misfolding
of proteins [32]. First of all, the lack of the cleaved form of CASP 3
(Figure 5A) highlighted that there was no activation of the
apoptotic programme; moreover, we observed the reduction in the
inactive form of the enzyme in the presence of mutated parkin
(Figure 5B, dark grey bars). On the other hand, mutant LRRK2
induced a significant reduction in HSP 70 (Figure 5B, light grey
bars); interestingly, this finding could explain the higher sensitivity
of LRRK2 mutant induced pluripotent stem cell (iPSC)-derived
dopaminergic neurons to CASP 3 activation [33]. On the
contrary, HSP 70 levels were hugely increased in fibroblasts from
idiopathic PD patients (Figure 5B, dark bars). As it has already
been reported that HSP 70 prevents MT assembly [34] and
stabilizes actin filaments [35], these results, together with the
reduction of GSK3b phosphorylation, could easily explain the
above reported MT destabilization and the increase in actin
filaments in idiopathic PD fibroblasts. Finally, we also looked at
microtubule-associated protein 1 light chain 3 (LC3) I and II, well
known markers of autophagy. The amount of LC3-II correlates
with the extent of autophagosome formation and the conversion of
LC3-I to LC3-II is a reliable indicator of autophagic activity [36].
Our results showed no significant changes in the levels of LC3-I
and LC3-II (Figure 5), and therefore in PD fibroblasts the
autophagic machinery is active at basal level. The levels of LC3-I
Figure 2. PD fibroblasts show subtle cytoskeleton differences. (A) Immunoblot and (B) densitometric analyses of vimentin (Vim), a-tubulin (a-
Tub), b-tubulin (b-Tub) and actin (Actin) were performed in whole cell extracts from human fibroblasts deriving from control (CONT, white bars,
N = 10), mutated parkin (PARK, dark grey bars, N = 6), mutated LRRK2 (LRRK2, light grey bars, N = 6) and idiopathic PD (PD, black bars, N = 3). For the
quantitation, values of each protein were normalized on the level of GAPDH of the relative sample. All values are expressed as mean6 SEM. *p,0.05
and ***p,0.005 vs control, ##p,0.02 vs PD, according to ANOVA, Tukey HSD post hoc test. (C) Cultured human fibroblasts were stained with anti-
vimentin and anti-a-tubulin primary antibodies or with TRITC-conjugated phalloidin to reveal the organization of intermediate filaments (Vim, top),
microtubules (a-Tub, middle) and actin fibers (Actin, bottom), respectively. Concurrent nuclear staining was made by using DAPI (Blue). Scale bar:
20 mm.
doi:10.1371/journal.pone.0037467.g002
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and -II in LRRK2-linked PD differed from those already reported
in knockout mice [37], suggesting that the lack or the mutation of
LRRK2 may affect autophagy differently. These data highlight
that there is no activation of stress-induced pathways in PD
fibroblasts. However, these fibroblasts show MT system alterations
that may eventually trigger neuronal death by other mechanisms.
Pharmacological Stabilization of MTs Rescues
Fibroblast Phenotype
To validate the idea that MTs and MT destabilization are
crucial players in altering cell functions and behaviors in PD
conditions, we decided to treat patient derived fibroblasts with
taxol (Figure 6), a potent MT stabilizer that has proven to be
neuroprotective in midbrain dopaminergic neurons in cultures
[14]. After 2 h of treatment with 10 mM of Taxol, tubulin was
completely shifted toward the Triton-insoluble fraction (Figure 6A),
meaning that there was an increase in the MT pool in patients
fibroblasts. The morphometric analyses (Figure 6B–D) showed
that the increase in MTs correlated with a correction of cell
morphology and behavior, pointed out by the increase of the ratio
between maximum and minimum axis and by the reduction of
overlapping regions. Furthermore, we treated control fibroblasts
with colchicine or nocodazole, two well known MT destabilizing
drugs. As expected, we observed almost all the tubulin associated
to the unpolymerized pool (Figure 6E), the reduction of the axes
ratio and the dramatic increase of overlapped cells (Figure 6F–H),
showing that a direct interference with the MT system is sufficient
to induce the same alterations we observed in PD fibroblasts
(Figure 1). Taken together, these data demonstrate that impair-
ment of MT stability in PD patient derived cells is directly
correlated to changes in morphology and behavior, and strongly
suggest that MT system may be a good ‘‘druggable’’ candidate for
restoring the proper cell mechanics.
Genetic Manipulation Restores MT Stability and Rescues
Fibroblast Phenotype
To further consolidate our results, we decided to perform rescue
experiments, by over-expressing the wild-type (WT) parkin or
LRRK2 in the fibroblasts from patients bearing the mutations in
parkin or LRRK2, respectively. Moreover, in order to validate the
idea that genetic manipulations of these proteins directly influence
MT system, and therefore cell architecture, we tried to affect
control fibroblasts either by parkin silencing or by mutant LRRK2
expression. As reported in figure 7A, transfection of WT parkin
increased polymerized MTs in patient fibroblasts, whereas parkin
silencing reduced MT fraction in control cells. Consistent with our
hypothesis, the analyses of cell morphology revealed that
expression of WT parkin increased the axes ratio and reduced
overlapping regions whereas its silencing exerted the opposite
effects (Figure 7B–D), mimicking changes observed in patient
fibroblasts. In the same way, over-expression of WT LRRK2 in
patient fibroblasts increased MT fraction (Figure 7E), and induced
a correction of cell morphology (Figure 7F–H), as highlighted by
increased ratio between maximum and minimum axis. Similarly,
the expression of mutant LRRK2 in control cells promoted MT
destabilization, represented by the increase of free tubulin
(Figure 7E), and worsened fibroblast morphology and behavior
(Figure 7F–H), as showed by the reduced axes ratio and by the
increased overlapping regions. Our data, not only demonstrate
that alteration of cell morphology and behavior in genetic PD
patient fibroblasts are dependent on impairment of MT stability,
but, further, our results make light on the capacity of WT parkin
or LRRK2 to correct cell defects by restoring MT stability. This
point is further sharpened by the absence of significant differences
between the morphology of patient fibroblasts transfected with
WT parkin or LRRK2 and the cells from healthy subjects
expressing control vectors, indicating that the correction of MT
system is sufficient to rescue the cell architecture. Together with
the pharmacological experiments, these data reinforce the idea of
a pivotal role of MT destabilization, and make concrete the
hypothesis of a possible MT-based PD therapy.
Discussion
In this study, we demonstrate that MT stability is impaired in
human fibroblasts derived from genetic PD patients and it is likely
compromised in idiopathic PD patients, reporting the alterations
Figure 3. Impairment of MT stability is shared by PD
fibroblasts. (A) Immunoblot and (B) densitometric analyses of Tyr,
deTyr, and Ac tubulin, were performed in whole cell extracts from
human fibroblasts deriving from control (white bars), mutated parkin
(dark grey bars), mutated LRRK2 (light grey bars) and idiopathic PD
(black bars). For the quantitation, values of each a-tubulin PTM were
normalized on the level of a-tubulin of the relative sample. Triton X-
100-soluble (free a-tubulin, Dim) and -insoluble fraction (a-tubulin
incorporated into MTs, MT) of human fibroblasts were analyzed by (C)
immunoblot and (D) densitometric analyses and are shown as ratio.
*p,0.05 and ***p,0.005 vs control, ##p,0.02 vs PD, according to
ANOVA, Tukey HSD post hoc test. All values are expressed as mean 6
SEM. CONT= control (N= 10); PARK=patients with mutations of parkin
(N = 6); LRRK2=patients carrying mutations in LRRK2 (N = 6); PD= idio-
pathic Parkinson’s disease patients (N= 3).
doi:10.1371/journal.pone.0037467.g003
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of a-tubulin PTMs and the significant MT depletion. It has been
already shown that human fibroblasts carrying parkin with the
deletion of the 4th exon, encoding the MT binding domains, show
a higher degree of MT depolymerization when they challenged
with a MT disruptor agent such as colchicine [27]. Here we report
that MT depolymerization occurs in PD fibroblasts even without
the addition of any stressor, and that MT destabilization seems to
be a common feature shared by idiopathic and genetic parkin-
sonism. It is noteworthy, as we demonstrate here, that both
pharmacological treatment and genetic approaches are able to
restore the proper MT stability and, therefore, to rescue cell
alterations deriving from MT destabilization. Thus, our work
highlights, for the first time, that MT dysfunction is present in
patients in baseline conditions and that correction of MT defects
recovers cell phenotype, underlining the central role of MT system
in PD.
Figure 4. GSK3b phosphorylation is reduced in PD fibroblasts. (A) Immunoblot and densitometric analyses of (B) total and (C)
phosphorylated glycogen synthase kinase 3 beta (GSK3b), p38 MAP Kinase (p38) and p44/42 MAPK (Erk) were performed in whole cell extracts from
human fibroblasts deriving from control (CONT, white bars, N = 3), mutated parkin (PARK, dark grey bars, N = 3), mutated LRRK2 (LRRK2, light grey
bars, N = 3) and idiopathic PD (PD, black bars, N = 3). For the quantitation, values of total protein were normalized on the level of GAPDH of the
relative sample, whereas the levels of phosphorylated form were normalized on the values of total protein. All values are expressed as mean 6 SEM.
*p,0.05 and **p,0.02 vs control, #p,0.05 vs PD according to ANOVA, Tukey HSD post hoc test.
doi:10.1371/journal.pone.0037467.g004
Figure 5. Stress-induced pathways are not activated in PD fibroblasts. (A) Immunoblot and (B) densitometric analyses of caspase 3 (CASP 3),
heat shock protein 70 (HSP 70) and microtubule-associated protein 1 light chain 3 (LC3) I and II were performed in whole cell extracts from human
fibroblasts deriving from control (CONT, white bars, N = 10), mutated parkin (PARK, dark grey bars, N = 6), mutated LRRK2 (LRRK2, light grey bars,
N = 6) and idiopathic PD (PD, black bars, N = 3). For the quantitation, values of each protein were normalized on the level of GAPDH of the relative
sample. All values are expressed as mean 6 SEM. *p,0.05 and ***p,0.005 vs control, ##p,0.02 vs PD according to ANOVA, Tukey HSD post hoc
test.
doi:10.1371/journal.pone.0037467.g005
Microtubule Destabilization in Parkinson’s Disease
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37467
Tubulin PTMs have recently been linked to neurodegener-
ative processes [38]. Our results, indeed, reveal the importance
of a-tubulin PTM dysregulation in PD etiopathogenesis. Being
Tyr tubulin the newly synthesized a-tubulin [8], the parkin-
induced enrichment of Tyr tubulin can be viewed as an attempt
to produce new MTs, as a consequence of the depolymerizaton
of the older MTs. In addition, it is a clear sign of the increase
of dynamic MTs. On the other hand, the enrichment of stable
MTs, observed in idiopathic PD and in patients carrying
mutations of LRRK2, could be the extreme effort of the cell to
stabilize a collapsing system. In any case, both the hyper-
dynamicity caused by mutant parkin and the over-stabilization
associated with LRRK2, actually represent an imbalance of MT
dynamics. Thus, the first outcome of our work is the suggestion
Figure 6. Pharmacological MT stabilization rescues fibroblast phenotype. (A) Representative immunoblot of Triton X-100-soluble (free a-
tubulin, S) and -insoluble fraction (a-tubulin incorporated into MTs, I) of patients fibroblasts treated with paclitaxel (Tax) or solvent (Met).
Morphometric analyses showing the ratio between maximum and minimum axes (B), the area (C) and the number of overlapping regions between
cells (D) of paclitaxel (TAX) or solvent (Met)-treated patient fibroblasts. ns = not significant, *p,0.05, **p,0.02 and ***p,0.005 according to ANOVA,
Tukey HSD post hoc test. All values are expressed as mean 6 SEM. PARK=patients with mutations of parkin (N = 4); LRRK2=patients carrying
mutations in LRRK2 (N = 3); PD= idiopathic Parkinson’s disease patients (N= 3). (E) Representative immunoblot of Triton X-100-soluble (free a-tubulin,
S) and -insoluble fraction (a-tubulin incorporated into MTs, I) of control fibroblasts treated with colchicine (COLC), nocodazole (NOC) or solvents
(DMSO or Met). Morphometric analyses showing the ratio between maximum and minimum axes (F), the area (G) and the number of overlapping
regions between cells (H) of colchine (COLC, N= 5), nocodazole (NOC, N = 5) or solvent (DMSO or Met, N= 5 respectively)-treated control fibroblasts.
ns = not significant and ***p,0.005 according to ANOVA, Tukey HSD post hoc test. All values are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0037467.g006
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of a new biological mechanism for LRRK2- and parkin-
mediated regulation of MT stability, i.e. the modulation of a-
tubulin PTMs.
Neurons are not-dividing cells with an extremely long life, and
in their axons accumulate very stable MTs, that remain for much
longer time than the usual MT half-life [39]. Thus, the
Figure 7. Genetic manipulation restores MT stability and rescues fibroblast phenotype. (A) Representative immunoblot of Triton X-100-
soluble (free a-tubulin, S) and -insoluble fraction (a-tubulin incorporated into MTs, I) of fibroblasts collected from patients with parkin mutations
(PARK) transfected with control plasmid (VEC) or WT parkin (WT), and of control fibroblasts (CONT) transfected with short hairpin RNA, sh-183 (183) or
control shRNA (VEC). (B-D) Morphometric analyses of patients fibroblasts expressing control plasmid (PARK-VEC, N = 4) or WT parkin (PARK-WT, N= 4),
and control fibroblasts transfected with control shRNA (CONT-VEC, N= 4) or silenced with sh-183 (CONT-183, N= 4), showing the ratio between
maximum and minimum axes (B), the area (C) and the number of overlapping regions between cells (D). ns = not significant, **p,0.02 and
***p,0.005 according to ANOVA, Tukey HSD post hoc test. All values are expressed as mean 6 SEM. (E) Representative immunoblot of Triton X-100-
soluble (free a-tubulin, S) and -insoluble fraction (a-tubulin incorporated into MTs, I) of fibroblasts collected from patients with LRRK2 mutations
(LRRK2) transfected with control plasmid (VEC) or WT LRRK2 (WT), and of control fibroblasts (CONT) expressing control plasmid (VEC) or G2019S
mutant LRRK2 (MUT). Morphometric analyses of patients fibroblasts expressing control plasmid (LRRK2-VEC, N= 3) or WT LRRK2 (LRRK2-WT, N = 3), or
of control fibroblasts transfected with control plasmid (CONT-VEC, N= 3) or G2019S mutant LRRK2 (CONT-MUT, N = 3), showing the ratio between
maximum and minimum axes (F), the area (G) and the number of overlapping regions between cells (H). ns = not significant, *p,0.05, **p,0.02 and
***p,0.005 according to ANOVA, Tukey HSD post hoc test. All values are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0037467.g007
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accumulation of aberrant tubulin dimers is likely to occur,
especially if tubulin turnover is compromised. This is exactly the
scenario we hypothesize for PD patients carrying parkin mutations
on the basis that parkin promotes ubiquitination and degradation
of tubulin [5] and that b-tubulin significantly increases in the
presence of mutated parkin, as we reported in the present work.
Moreover, a particularly long life of MTs could lead to an
unconventional subset of tubulin PTMs, and the impairment of
tubulin PMTs could have further impacts on neuronal functions,
being crucial for the regulation of various MT-dependent
functions. Through the modulation of binding and velocity of
motor proteins, tubulin PTMs are supposed to be involved in the
regulation of axonal transport [40] whose impairment has recently
been suggested as a common and early event in neurodegener-
ation [41]. We have previously reported that imbalance of a-
tubulin PTMs results in impairment of axonal transport and in
mitochondrial damage in PC12 cells exposed to MPP+ [15]. Here
we show that parkin and LRRK2 modulate tubulin PTMs,
offering alternative explanations for the reported capacity of
parkin to arrest the movement of damaged mitochondria [42] and
for the ability of LRRK2 to modulate trafficking and distribution
of synaptic vesicles in cortical neurons [43]. Furthermore, we
observe the significant activation of GSK3b in PD fibroblasts, that
with its upstream and downstream regulators has key roles in
many neuronal processes [28], as neurite outgrowth, neuronal
polarization and, perhaps, axonal transport. Active GSK3b
phosphorylates MAPs with the consequent MT depolymerization
and the breakdown of the railways along which motor proteins
move; therefore, an increase in GSK3b activation can likely affect
axonal transport. Thus, having shown the ability of parkin and
LRRK2 to modulate tubulin PTMs and MT-related signaling
pathways, the present paper could be a good starting point to
analyze the ability of parkin and LRRK2 to regulate axonal
transport.
The proper regulation of MT dynamics is critical for the
survival and for the establishment of cell-cell contacts in different
cell types [44,45]. For example, when fibroblasts collide they
undergo contact inhibition of locomotion that involves cell
retraction and reversal of polarity, allowing cells to change the
direction of migration and to move in a cell free environment.
During aging, fibroblasts motility declines contributing to deficits
in wound-healing, and this impaired behavior has been associated
to disorganization of actin cytoskeleton [46]. Further data
confirmed that mechanical properties are altered in consequence
to the increased amount of polymerized actin in fibroblasts from
old donors, whereas no significant changes in vimentin or MTs
content are associated with aging process [47]. Very recently,
Kadir and colleagues [45] have shown that this behavior resides
on the fine tuning of MT dynamics and organization, especially at
the sites of cell contact, where MT dynamics shall rise above a
threshold to permits contact inhibition of locomotion; they also
reported that Y24632-treated cells, which have hyper-stable MTs,
are unable to re-orientate. Here, we demonstrate that PD patient
fibroblasts have altered morphology and spatial organization that
could be explained by the increased of stable MTs in LRRK2 and
idiopathic PD, but also by the spreading of Ac MTs in all PD
fibroblasts, that would locally interferes with the acceptable MT
dynamics. Therefore, our data show that changes in MT stability
are specifically associated to PD conditions and suggest that PD
pathology could reside on compromised cell mechanics due to a
failure of the MT system. This idea is strengthened by the fact that
the administration of taxol, a MT stabilizing agent, or the
expression of either WT parkin or WT LRRK2 in PD patient
fibroblasts, provokes an increase in the polymerized MTs and a
recovery of the cell morphology and behavior. Interestingly, the
MT destabilization observed in patient fibroblasts unravels a
possible intrinsic MT weakness in PD affected people that could be
crucial for neuronal survival and especially for dopaminergic
neurons, being shown to be particularly vulnerable to the
colchicine-induced MT depolymerization [14,48].
Mitochondrial dysfunction has been related to the pathogenesis
of PD for a long time, and recent papers show that both parkin
[17] and LRRK2 [18] can be important for the regulation of
mitochondria function and malfunction. In the last few years,
tubulin has proved to be able to modulate mitochondrial
respiration through its interaction with voltage-dependent anion
channels, the most abundant protein in the mitochondrial outer
membrane. In particular, it has been reported that tubulin
decreases the respiration rate of isolated mitochondria [49] and
that the increase in tubulin dimers induces mitochondrial
depolarization in human cancer cells [50]. Under this light, the
increased amount of free tubulin we observed in human PD
fibroblasts could be responsible for the mitochondrial alterations in
these cells, described elsewhere [17,18]. Thus, as we and others
have already suggested [14,15,51], MTs and mitochondria
collaborate in producing dopaminergic neuron death in PD.
Taken together, our results highlight, for the first time, that
proteins associated with PD, such as parkin and LRRK2, have an
impact on MT organization and stability in humans, and that
idiopathic PD seems to display MT impairment as well.
Furthermore, our analyses reveal that these MT alterations
profoundly affects cells morphology and behavior, but also that
MT stabilization, by taxol treatment or by expression of WT
parkin or WT LRRK2, is sufficient to restore the correct cell
mechanics. The groundbreaking technique of iPSC-derived
dopaminergic neurons [52] offers the noteworthy advantage of
recapitulating key molecular aspects in a human model of
neurodegeneration, and, moreover, iPSCs enable the production
of patient-specific cell lines, with the potential use for high-
throughput drug screening and personalized therapies. We will
move onto this exciting field soon to validate in human neurons
the occurrence of MT dysfunction and to seek a possible MT-
based therapy, trying to transfer to neurons our actual findings in
human fibroblasts as well as to deeper investigate the biological
relationship among parkin, LRRK2 and MTs. Thus, the present
work can be the launch pad for the study of MT system in PD
patients.
Supporting Information
Figure S1 Age distribution in the experimental groups.
Scatter plot representing the age distribution of the individuals in
each experimental group. CONT= control (N=10); PARK=pa-
tients with mutations of parkin (N= 6); LRRK2=patients carrying
mutations in LRRK2 (N= 6); PD= idiopathic Parkinson’s disease
patients (N=3). Statistical analyses did not reveal differences in
age between control or patient groups (p=0.168 according to
ANOVA).
(TIF)
Figure S2 Parkin over-expression and silencing. (A)
Representative micrographs of cultured fibroblasts deriving from
PD affected patients bearing parkin mutation transfected with
control plasmid (PARK+VEC) or WT parkin (PARK+WT). Scale
bar: 20 mm. (B) Representative immunoblot of parkin performed
on cultured fibroblasts deriving from healthy subjects transfected
with control shRNA (CONT+VEC) or silenced with sh-183
(CONT+183).
(TIF)
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Figure S3 PD fibroblasts show altered a-tubulin PMT
staining. Human fibroblasts were immunostained for Tyr, deTyr
and Ac tubulin, to investigate MT organization and stability. All
cells were concurrently stained with DAPI (blue), to visualize the
nucleus. Scale bar: 25 mm. CONT= control; PD= idiopathic
Parkinson’s disease; PARK=patients with mutations of parkin;
LRRK2=patients carrying mutations in LRRK2.
(TIF)
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